New therapy for colorectal cancer targeting cancer metabolism through serotonin receptor HTR2B
Serotonin is important material in our body. 5-HT is synthesized by TPH1 starting with tryptophan and this compound exists on colorectal cancer. And serotonin combines with various receptors to conduct the metabolic pathway in colorectal cancer. Each receptor relates with various metabolism, such as lipid metabolism, growth, immunity, etc. In this way, medicine which inhibits these receptors can expect for therapy of colorectal cancer. Especially HTR 2B has correlation with growth factor and using the inhibitor of HTR2B, SB204741, can have effect on metabolic pathway in colorectal cancer. So, we set the hypothesis that HTR2B antagonist can have negative effect on growth of colorectal cancer. Overall design: We treated the SB204741 in vitro on Colo 205, we isolated RNA from the cell and tissue and conducted the analysis of RNA sequence